Skip to main content

Table 6 Late toxicity assessment (based on Modified LENT SOMA)

From: A biologically competitive 21 days hypofractionation scheme with weekly concomitant boost in breast cancer radiotherapy feasibility acute sub-acute and short term late effects

  G1 G2 G3 G4 N0 of patients
At 6 months (subacute)      
   Hyperpigmentation 22 (34%) 4 (6%) 0 0 65
At 12 months      
   Fibrosis 28 (43%) 2 (3%) 0 0 65
   Hyperpigmentation 3 (5%) 0 0 0 65
At 24 months*      
   Fibrosis 25 (45%) 2 (3%) 0 0 56
   Hyperpigmentation 0 0 0 0 56
  1. * A total of 56 patients seen at 24 months or more with 29 (52%) free of side effects.